Efficacy, Safety, Tolerability, Immunogenicity and Pharmacokinetic Evaluation of HYQVIA in Pediatric PIDD Subjects
Public ClinicalTrials.gov record NCT03277313. Field values are reproduced from the official study page; the official ClinicalTrials.gov record remains the source of truth for eligibility, enrollment, and contact information.
Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.
Official title
Efficacy, Safety, Tolerability, Immunogenicity and Pharmacokinetic Evaluation of HYQVIA in Pediatric Subjects With Primary Immunodeficiency Diseases
Study identification
- NCT ID
- NCT03277313
- Recruitment status
- Completed
- Study type
- Interventional
- Phase
- Phase 3
- Lead sponsor
- Baxalta now part of Shire
- Industry
- Enrollment
- 44 participants
Conditions and interventions
Conditions
Interventions
- HYQVIA Biological
Biological
Eligibility (public fields only)
- Age range
- 2 Years to 15 Years
- Sex
- All
- Healthy volunteers
- Healthy volunteers not accepted
This page does not interpret eligibility. Detailed inclusion and exclusion criteria are on the official ClinicalTrials.gov record.
Study timeline
- Start date
- Sep 24, 2017
- Primary completion
- Jul 19, 2022
- Completion
- Jul 19, 2022
- Last update posted
- Oct 22, 2023
2017 – 2022
United States locations
- U.S. sites
- 19
- U.S. states
- 13
- U.S. cities
- 18
| Facility | City | State | ZIP | Site status |
|---|---|---|---|---|
| University of Alabama Medical Center | Birmingham | Alabama | 35294 | — |
| Connecticut Children's Medical Center | Hartford | Connecticut | 06106 | — |
| University of Miami Pediatric Allergy and Immunology | Miami | Florida | 33136 | — |
| University of South Florida Physician Group | St. Petersburg | Florida | 33701 | — |
| Georgia Pollens Clinical Research Centers, Inc. | Albany | Georgia | 31707 | — |
| Emory Healthcare | Atlanta | Georgia | 30322 | — |
| Boston Children's Hospital | Boston | Massachusetts | 02115 | — |
| Washington University | St Louis | Missouri | 63110 | — |
| Women & Children's Hospital of Buffalo | Buffalo | New York | 14203 | — |
| Northwell Health, Inc. PRIME | Great Neck | New York | 11021 | — |
| Stony Brook Children's Hospital | Stony Brook | New York | 11794 | — |
| Carolinas Healthcare System | Charlotte | North Carolina | 28203 | — |
| Allergy Asthma & Immunology Relief of Charlotte | Charlotte | North Carolina | 28277 | — |
| OK Institute of Allergy & Asthma Clinical Research, LLC | Oklahoma City | Oklahoma | 73131 | — |
| Vital Prospects Clinical Research Institute, P.C. | Tulsa | Oklahoma | 74136 | — |
| Allergy Partners of North Texas Research | Dallas | Texas | 75230 | — |
| University of Utah | Salt Lake City | Utah | 84132 | — |
| Section on Immunopathogenesis and Clinical Immunology | Fairfax | Virginia | 22030 | — |
| Marshall University Joan C. Edwards School of Medicine | Charleston | West Virginia | 25701 | — |
Site contact phone numbers, emails, and investigator names are intentionally not displayed here. Open the official ClinicalTrials.gov record for site contact information.
About this trial record page
- What this page shows
- Public field values for ClinicalTrials.gov record NCT03277313, including study identification, conditions, interventions, eligibility (age, sex, healthy volunteer), timeline, and U.S. site list.
- What this page does not do
- No medical advice, eligibility judgments, treatment recommendations, study quality scoring, or AI-generated medical summaries. No site contact phone numbers, emails, or investigator names.
- Where the data comes from
- Sourced from the official ClinicalTrials.gov public API. The official record is the source of truth.
- Last refresh
- Last update posted Oct 22, 2023 · Synced Jul 21, 2026
Related: full search, browse by condition, browse by drug or therapy, browse by sponsor, browse by U.S. city.
Open the official record
The complete protocol, eligibility criteria, and contact information for NCT03277313 live on ClinicalTrials.gov.